Phreesia (NYSE:PHR) Insider Yvonne Hui Sells 1,327 Shares

Phreesia, Inc. (NYSE:PHR) insider Yvonne Hui sold 1,327 shares of the stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $9.28, for a total value of $12,314.56. Following the transaction, the insider directly owned 24,664 shares in the company, valued at approximately $228,881.92. This represents a 5.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Yvonne Hui also recently made the following trade(s):

• On Thursday, April 16th, Yvonne Hui sold 10,063 shares of Phreesia stock. The stock was sold at an average price of $9.08, for a total value of $91,372.04.

Phreesia Trading Down 1.1%

NYSE:PHR opened at $9.33 on Wednesday. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The business’s 50 day moving average is $10.82 and its two-hundred day moving average is $16.01. Phreesia, Inc. has a 52 week low of $7.77 and a 52 week high of $32.76. The company has a market cap of $566.59 million, a PE ratio of 310.83 and a beta of 0.86.

Phreesia (NYSE:PHR) last released its earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The firm had revenue of $127.07 million for the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The company’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.11) EPS. On average, analysts predict that Phreesia, Inc. will post 0.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wall Street Zen downgraded Phreesia from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Robert W. Baird reissued a “neutral” rating and issued a $10.00 price target (down from $25.00) on shares of Phreesia in a report on Tuesday, March 31st. Canaccord Genuity Group cut their price target on Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Mizuho cut their price target on Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, March 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a report on Wednesday, January 28th. Twelve research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.82.

Institutional Trading of Phreesia

Large investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. bought a new stake in Phreesia during the 3rd quarter valued at $32,000. Asset Management One Co. Ltd. bought a new stake in Phreesia during the 3rd quarter valued at $45,000. Van ECK Associates Corp raised its stake in Phreesia by 78.7% during the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after acquiring an additional 1,102 shares in the last quarter. Rockefeller Capital Management L.P. raised its stake in Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after acquiring an additional 2,149 shares in the last quarter. Finally, KBC Group NV raised its stake in Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after acquiring an additional 1,568 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.